Buy
Average AnalystBuy
Top AnalystBullish
Stock Target AdvisorStrong Buy
Average UserUSD 108.85
-1.12 (-1.02)%
USD 21.28B
2.09M
USD 123.15(+13.13%)
Symbol | Name | Exchange | ZBH's Weight | Expense Ratio | Price(Change) | Market Cap |
---|---|---|---|---|---|---|
|
VanEck Bionic Engineering.. | XETRA | 5.65 % | 0.00 % | -0.13 (-0.67%) | USD4.90M |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
This stock has shown below median revenue growth in the previous 5 years compared to its sector